In 2015, a EULAR task force released evidence-based recommendations on the use of imaging in the clinical management of spondyloarthritis, including psoriatic arthritis. These recommendations, together with articles dealing with tight control strategies and use of the IL-17A inhibitor secukinumab, have consolidated progress in the management of psoriatic arthritis.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Oligoarticular Psoriatic Arthritis: Addressing Clinical Challenges in an Intriguing Phenotype
Rheumatology and Therapy Open Access 01 June 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Olivieri, I., D'Angelo, S., Palazzi, C. & Padula, A. Advances in the management of psoriatic arthritis. Nat. Rev. Rheumatol. 10, 531–542 (2014).
Mandl, P. et al. EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice. Ann. Rheum. Dis. 74, 1327–1339 (2015).
Smolen, J. S. et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann. Rheum. Dis. 73, 6–16 (2014).
Coates, L. C. et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet http://dx.doi.org/10.1016/S0140-6736(15)00347-5 (2015).
Coates, L. C. & Helliwell, P. S. Validation of minimal disease activity (MDA) criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res. (Hoboken) 62, 965–969 (2010).
Haroon, M., Gallagher, P. & FitzGerald, O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann. Rheum. Dis. 74, 1045–1050 (2015).
Ritchlin, C. et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann. Rheum. Dis. 73, 990–999 (2014).
Kavanaugh, A. et al. Treatment of psoriatic arthritis in a phase 3 randomized, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann. Rheum. Dis. 73, 1020–1026 (2014).
Mease, P. J. et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N. Engl. J. Med. 373, 1329–1339 (2015).
McInnes, I. B. et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet 386, 1137–1146 (2015).
Acknowledgements
The author wishes to thank Enrico Scarano (Radiology Department, San Carlo Hospital, Potenza), for assistance with the images for Fig. 1.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors have received honoraria from Abbvie, BMS, Celgene, MSD, Novartis, Pfizer, Roche, and UCB to attend scientific meetings. The authors have received no payment in the preparation of this manuscript.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Olivieri, I., D'Angelo, S. Advancement continues in imaging, tight control and new drugs. Nat Rev Rheumatol 12, 76–78 (2016). https://doi.org/10.1038/nrrheum.2015.184
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2015.184
This article is cited by
-
Oligoarticular Psoriatic Arthritis: Addressing Clinical Challenges in an Intriguing Phenotype
Rheumatology and Therapy (2018)
